Introduction Loss of interferon-γ (IFN-γ) function through the development of neutralizing autoantibodies results in a late-onset immunodeficiency characterized by disseminated opportunistic infection. While rare, there is a higher prevalence in patients of Southeast Asian ancestry. Treatment is aimed at B cell depletion; however, relapse is common. Here we describe two cases of anti–IFN-γ autoantibody-associated immunodeficiency. Case Descriptions Patient 1: A 42-year-old female originally from Laos presented with a 30-lb weight loss and fatigue over the course of 8 months. Cultures grew Mycobacterium hassiacum. Testing by National Jewish was positive for anti–IFN-γ autoantibody via ELISA and for IFN-γ neutralizing ability via pSTAT1 phosphorylation. Autoantibodies were treated with rituximab 375 mg/m2 weekly for 4 weeks. She had subsequent negative autoantibody levels for 6 months until positive autoantibodies were again detected. She was treated with an additional 3 rituximab 375 mg weekly infusions and maintained remission for an additional 15 months until autoantibody levels were again positive without associated symptoms or infection (see table for timeline). She is currently undergoing additional 4 rituximab infusions. Table Patient 2 A 59-year-old female originally from Laos who presented for an immunodeficiency workup with a history of disseminated Mycobacterium avium infection, with pulmonary, lymph node, and parotid gland involvement. Anti–IFN-γ autoantibody testing from National Jewish was positive. She was treated with rituximab 375 mg/m2 weekly for 4 weeks. Autoantibody levels were negative 3 months later, and she has maintained remission since by serial monitoring. Discussion In our experience, anti–IFN-γ autoantibody-associated secondary immunodeficiency should be suspected in middle-aged patients with disseminated opportunistic infection, especially women of Southeast Asian ancestry. Rituximab rapidly depletes autoantibody levels; however, maintenance of remission is variable. The average duration of response in patient 1 was 10.5 months compared with persistent remission in patient 2. Thus, serial monitoring with autoantibody levels, markers of inflammation, and symptom assessments should be performed with consideration for repeated doses of rituximab.
Biallelic DUOX2 Variants and the Link to Very Early-Onset IBD
Introduction Very early-onset inflammatory bowel disease (VEO-IBD) involves children less than 6 years of age presenting with IBD. These patients are more likely to have inborn errors of immunity. We present a child with VEO-IBD, found to have compound heterozygous variants in the DUOX2 gene that expands on the rare association of VEO-IBD with DUOX2 insufficiency. Case Description A 5-year-old male presented with six months of watery diarrhea, with labs notable for thrombocytosis, elevated CRP, and fecal calprotectin to 1430 [ref ≤ 49 μg/g]. Endoscopy and colonoscopy with biopsy revealed intraepithelial lymphocytosis in the duodenum, eosinophilic infiltrate in the stomach, esophagitis without eosinophilia, and chronic active ileitis with eosinophils of 65/hpf in the terminal ileum, consistent with a diagnosis of Crohn’s disease. The patient underwent immune phenotyping given his young age, which revealed elevated sIL2R, IL-17, IL-5, IL-13, IL-10, and IL-6, T cell lymphocytosis, and a normal neutrophil oxidative burst. Targeted genetic sequencing revealed two heterozygous variants in the DUOX2 gene: one maternally inherited likely pathogenic splice site variant, c.2922-14_2925del; and one paternally inherited variant of uncertain significance (VUS), c.1528C>T (p.Arg510Trp). The VUS is within the peroxidase-like region of the gene, which plays a crucial role in enzyme function, has a high CADD score of 25, and has a GnomAD allelic frequency of only 0.001%, suggesting possible pathogenicity. The patient is currently doing well on infliximab, with interval normalization of his cytokines. Discussion The DUOX2 gene encodes for dual NADPH oxidase (DUOX), which is responsible for the release of hydrogen peroxide as part of the innate immune defense of gut epithelial cells. In mice, DUOX2 has been shown to play an integral role in maintaining immune homeostasis in the gut biome, with knockout models showing elevated IL-17C levels in the ileum. There are few reported cases describing the association of compound heterozygous variants in DUOX2 in patients with VEO-IBD, with this being the fourth patient, to the best of our knowledge. This case highlights the importance of further research to better understand the role of this gene in the development of inflammatory bowel disease. Table 1.DiagnosticsValueCytokine panelIL-2 <2.1 (ref range ≤ 2.1)IL-2R 2259.3 (ref range 175.3 - 858.2)IL-12 <1.9 (ref range ≤ 1.9)INF- γ <4.2 (ref range ≤ 4.2)IL-4 <2.2 (ref range ≤ 2.2)IL-5 19.1 (ref range ≤ 2.1)IL-10 11.1 (ref range ≤ 2.8)IL-13 2.5 (ref range ≤ 2.3)IL-17 5.5 (ref range ≤ 5.5)IL-1β <6.5 (ref range ≤ 6.7)IL-6 6.3 (ref range ≤ 2.0)TNF-α 2.5 (ref range ≤ 7.2)ImmunoglobulinsIgA – 69 (ref range 21 – 144)IgE – 4680 (ref range 2 – 524)IgG – 734 (498 – 1332)IgM – 82 (ref range 31 – 63)Lymphocyte subset panelAbsolute CD3 3080 (ref range 1400 – 3700)Absolute CD4 1969 (ref range 700 – 2200)Absolute CD8 876 (ref range 490 – 1300)Absolute CD45RA 1505 (ref range 430 – 1500)Absolute CD45RO 652 (ref range 220 – 660)Absolute HLADR 660 (ref range 50 – 180)Absolute CD19 594 (ref range 390 – 1400)Absolute CD20 552 (ref range)Absolute NK 170 (ref range 130 – 720)EGD/ColonoscopyDuodenum - Intraepithelial lymphocytosisEsophagus mid and distal – esophagitis up to 2 eos/hpfEsophagus upper – esophagitis up to 1 eos/hpfChronic active ileitis with eosinophils (up to 65/hpf)Neutrophil oxidative burstNormal granulocyte dihydrohodamine fluorescence suggesting normal NADPH oxidase activityPrimary immunodeficiency panel1. DUOX2a. c.2922-14_2925del (splice site). Het. Likely pathogenic. GnomAD AC 99. CADD 31.b. c.1528C>T (p.Arg510Trp). Het. VUS. GnomAD AC 3. CADD 25. Peroxidase-like region (mediates peroxidase activity).2. FOXI3a. c.713G>A (p.Arg238Gln). Het. VUS. GnomAD AC 3. CADD 28.8. Associated with T cell lymphopenia. Not clinically relevant.3. MS4A1a. c.352A>C (p.Ile118Leu). Het. VUS. CADD 17.01. Conflicting in silico prediction models. GnomAD AC 71. Associated with CVID. Not clinically relevant.4. POLD1a. c.520C>T (p.Arg174Trp). Het. VUS. Associated with AD mandibular hypoplasia, deafness, progeroid features and lipodystrophy and AR T cell immunodeficiency. GnomAD AC 12. Not clinically relevant.
Anti-Vedolizumab Abrogates False-Positive Allogeneic T and B Cell Flow Cytometry Crossmatches in Solid Organ Transplantation
Aim Vedolizumab is a humanized monoclonal antibody that binds to α4β7 integrin expressed on most leukocytes and is used for treatment of inflammatory bowel disease. The objective of this study was to assess the effect of recombinant anti-vedolizumab treatment in vitro on allogeneic T and B cell flow cytometry crossmatches (FCXM) in solid organ transplantation. Methods Serum samples from kidney transplant recipients that received parenteral therapeutic vedolizumab monoclonal antibody injection 5 days prior to collection were used in the study. All serum samples were tested for the presence of HLA donor-specific antibodies (DSA) by Luminex single antigen beads assay (Thermo Fisher-One lambda). FCXM were performed using surrogate lymphocytes and sera were treated with heat inactivation (HI, 56°C for 30 mins), dithiothreitol (DTT, 5 mM at 37°C for 15 mins), and inhibitory anti-idiotypic recombinant anti-vedolizumab antibodies (HCA292, Bio-Rad, at 0.1, 0.05, and 0.025 mg/ml at room temperature for 30 min). Results Parenteral administration of therapeutic vedolizumab monoclonal antibodies caused false-positive allogeneic T and B cell FCXM in the absence of HLA DSA. HI and DTT treatment of sera had no effect on the false-positive T and B cell FCXM. However, recombinant anti-vedolizumab antibodies successfully abrogated the false-positive T and B cell FCXM at 0.1 mg/ml and 0.05 mg/ml concentrations (Table 1). Anti-vedolizumab antibodies at 0.1 mg/ml concentration had no effect on the negative and positive crossmatch control serum. Table 1.Serum treatmentFlow cytometry crossmatchT cellB cellHeat inactivationpositivepositiveDTTpositivepositiveAnti-vedoluzimab 0.1mg/mlnegativenegativeAnti-vedoluzimab 0.05mg/mlnegativenegativeAnti-vedoluzimab 0.025mg/mlpositivepositive Conclusions This is the first report showing that therapeutic administration of vedolizumab monoclonal antibodies cause false-positive T and B cell FCXM in absence of HLA DSA, which can preclude from proceeding with allogeneic transplantation. In addition, recombinant anti-vedolizumab antibodies abrogated false-positive allogeneic T and B cell FCXM.
Genotype–Phenotype Correlations in Patients with STAT1 Gain-of-Function Mutations: A Case Series
Introduction STAT1 gain-of-function (GOF) mutations result in a broad clinical spectrum characterized by complex phenotypic manifestations. In addition to the hallmark chronic mucocutaneous candidiasis (CMC), patients are predisposed to bacterial and viral infections, autoimmunity, endocrinopathies, lymphoproliferative disorders, and malignancies. Severe complications, including invasive infections, cerebral aneurysms, and malignancies, are significant predictors of poor outcomes. Understanding genotype–phenotype correlations is critical for optimizing management in this challenging patient population. Methods We conducted a retrospective review of electronic medical records for five patients diagnosed with STAT1 GOF mutations at Mayo Clinic, Rochester, MN. This case series included data on demographics, clinical history, immunologic evaluations, genetic testing results, disease manifestations, treatments, and outcomes. Results The cohort included five patients (1 male, 4 females; mean age at diagnosis: 21.7 years) with heterozygous STAT1 GOF mutations. Three patients had c.1154C>T (p.Thr385Met), one had c.1310C>T (p.Thr437Ile) in the DNA-binding domain (DBD), and one had c.856A>G (p.Lys286Glu) in the coiled-coil domain (CCD). Universal features included CMC and recurrent sinopulmonary infections. Patients with c.1154C>T presented with early-onset infections, severe autoimmunity (e.g., pancytopenia and enteropathy), and bronchiectasis, requiring ruxolitinib in all three cases. The patient with c.1310C>T had a late childhood onset of symptoms, later complicated by persistent histoplasmosis. The c.856A>G case experienced severe multidrug-resistant infections, splenomegaly, coagulopathy, neurological complications, poor response to ruxolitinib, and died from complications of MSSA pneumonia and monkeypox. Conclusion Genotype–phenotype correlations in STAT1 GOF mutations highlight a diverse clinical spectrum driven by mutation-specific mechanisms. DBD mutations are associated with more severe outcomes, including early-onset immunodeficiency, invasive infections, and autoimmunity, due to faster nuclear accumulation and impaired dephosphorylation of STAT1. CCD mutations present with multisystem involvement, further emphasizing the heterogeneity of clinical manifestations. These variations underscore the importance of genetic insights for prognostication and tailored management. Early interventions, including hematopoietic stem cell transplantation for severe cases, and emerging therapies like JAK inhibitors show promise; however, ruxolitinib's need for individualized dosing, vigilant monitoring, continuous treatment to maintain benefits, and lack of epigenetic correction warrant further evaluation.
Clinical Insight of Cytokine Panel Testing in Patients with Inborn Errors of Immunity
Background Cytokines play an important role in Th1 and Th2 inflammation. Both Th1 and Th2 cytokines can be utilized for evaluation and treatment response in many different disorders, including inborn errors of immunity. The role of broad cytokine panel testing in inborn errors of immunity is not well described. Objective To analyze broad cytokine panel testing in clinical practice. Methods A retrospective review of cytokine panel testing performed at Mayo Clinic was performed. Data were collected from patients at Mayo Clinic Rochester, Mayo Clinic Jacksonville, and Mayo Clinic Health System. Serum cytokine panel testing included the following cytokines: tumor necrosis factor (TNF), IL-6, IFN-β, IL-10, monocyte chemoattractant protein-1 (MCP-1), IL-1β, IFN-γ, macrophage inflammatory protein-1 alpha (MIP-1α), granulocyte-monocyte colony-stimulating factor (GM-CSF), IL-2 receptor α soluble, IFN-α, and IL-18. Data collection ranged from 03/2021 to 09/2024. The study was funded by Mayo CCaTS grant number UL1TR002377. Results A total of 88 cytokine panel tests were performed during the study period on 80 total patients. There was at least 1 elevated cytokine level in 70/88 (80%) tests performed. There was elevation in each individual cytokine level as follows: TNF (49), IL-2 receptor α soluble (40), IFN-α (0), IL-18 (26), IL-6 (33), IFN-β (4), IL-10 (13), MCP-1 (18), IL-1β, IFN-γ (11), MIP-1α (12), and GM-CSF (6). 18 patients that underwent cytokine panel testing had common variable immune deficiency (CVID), and 10 of those patients had granulomatous lymphocytic interstitial lung disease. 6 patients with early onset inflammatory bowel disease, 5 patients with autoimmune lymphoproliferative syndrome, 2 patients with Myhre syndrome, 2 patients with Hyper IgE syndrome, 1 patient with hypereosinophilic syndrome, 1 patient with autoimmune polyglandular syndrome type 1, 1 patient with XIAP deficiency, 1 patient with X-linked chronic granulomatous disease, and 1 patient with STAT 1 gain of function were tested. Other patients tested had other medical diagnoses or were undergoing immunodeficiency evaluation. There was no significant increase noted in any individual cytokine level when compared with the whole cohort. Conclusion Cytokine panel testing could be a potential diagnostic tool in evaluation of inborn errors of immunity. Further research is needed to better characterize the importance of cytokine panel testing in inborn errors of immunity.
A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial
ABSTRACT Knowledge of Treponema pallidum subspecies pallidum ( TPA ) outer membrane protein (OMP) sequence variability is essential for understanding spirochete proliferation within endemic populations as well as design of a globally effective syphilis vaccine. Our group has identified extracellular loops (ECLs) of TPA BamA (TP0326) and members of the FadL family (TP0548, TP0856, TP0858, TP0859, and TP0865) as potential components of a multivalent vaccine cocktail. As part of a consortium to explore TPA strain diversity, we mapped the variability of BamA and FadL orthologs in 186 TPA strains from Malawi, China and Colombia onto predicted 3D structures. The 186 genomes fell into eight subclades (five Nichols-, three SS14-lineage) with substantial geographic restriction. Single nucleotide variants accounted for the large majority of proteoforms, with variability notably higher within the Nichols-lineage strains. Most mutations were in regions of the proteins predicted to be extracellular and harboring B cell epitopes. We observed a striking difference in the degree of variability between the six OMPs, suggesting that these proteins are following divergent evolutionary paths. Concatenation of OMP sequences recapitulated the phylogenetic structure of the TPA strains, effectively segregating within clades and largely clustering by subclades. Lastly, we noted that BamA and FadL candidate ECL vaccinogens previously shown to elicit antibodies that kill treponemes during in vitro cultivation are well conserved. Taken as a whole, our study establishes a structural-phylogenetic approach for analyzing the forces shaping the host-pathogen interface in syphilis within endemic populations while informing selection of vaccine targets. IMPORTANCE Syphilis remains a major global health concern, reinforcing the need for a safe and effective vaccine. Understanding the variability of TPA OMPs is essential for tracking pathogen evolution and informing vaccine design. Here, we analyzed the variability of six TPA OMPs in 186 strains from Malawi, China, and Colombia, identifying protein-specific evolutionary patterns. Most mutations were localized in extracellular regions and, notably, appeared to correlate with the phylogenetic structure of TPA . Despite OMP heterogeneity, several candidate vaccinogens remained highly conserved, reinforcing their potential as globally effective vaccine targets. Our study establishes a structural-phylogenetic framework for dissecting the forces shaping the host-spirochete interface within endemic populations and provides a foundation for designing a globally effective syphilis vaccine.
The Rise of Medicare Advantage is Impacting the Fidelity of Traditional Medicare Claims Data
Background: Traditional Medicare (TM) claims data are widely used by researchers and registries to report survivorship following total knee arthroplasty (TKA). The purpose of the present study was to investigate whether the mass exodus of patients from TM to Medicare Advantage (MA) has compromised the fidelity of TM data. Methods: We identified 11,717 Medicare-eligible patients (15,282 knees) who had undergone primary TKA from 2000 to 2020 at a single institution. Insurance type was analyzed, and 84% of TKAs were covered by TM. The rates of survivorship free from revision or reoperation were calculated for patients with TM coverage. The same survivorship end points were recalculated after censoring of patients who transitioned to MA after primary TKA, thereby modeling the impact of losing patients from the TM dataset. Differences in survivorship were compared. The mean duration of follow-up was 10 years. Results: From 2000 to 2020, there was a decrease in TM insurance (from 94% to 68%) and a corresponding increase in MA insurance (from 0% to 19%) among patients undergoing TKA. Following TKA, 25% of patients with TM coverage switched to MA. For patients with TM at the time of surgery, the 15-year rates of survivorship free from any reoperation or revision were 90% and 96%, respectively. When patients were censored upon transition from TM to MA, the 15-year rates of survivorship free from any reoperation (92% versus 90%; hazard ratio [HR] = 1.2; p = 0.001) or any revision (97% versus 96%; HR = 1.3; p = 0.002) were significantly higher. Conclusions: One in 4 patients left TM for MA after primary TKA, effectively making them lost to follow-up within TM datasets. The mass exodus of patients out of TM resulted in falsely elevated estimates of survivorship free from reoperation and from revision, with increasing divergence in survivorship over time, when MA data were excluded. As MA continues to grow, efforts to incorporate these data will become increasingly important. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Photon-counting detector CT in paediatric imaging: a review of current literature and future directions
Abstract The benefits of photon-counting detector (PCD) CT include improved spatial resolution, increased radiation dose efficiency, and the elimination of electronic noise. Unlike traditional energy-integrating-detector (EID) CT systems, PCDs have inherent spectral capabilities, which support “always-on” dual energy and multi-energy imaging acquisition. PCD-CT directly converts X-ray photons into electrical signals and captures their individual energy levels. Current commercially available PCD-CT scanners, all from one manufacturer, include 2 models that incorporate dual-source geometry. This innovation is particularly advantageous for paediatric imaging by enabling rapid scans that reduce motion artifact and therefore the need for sedation and can now be combined in the current model with multi-energy imaging or ultra-high-resolution acquisition. This review article explores how the technical benefits of PCD CT improve the diagnostic quality of images and opens the field of paediatric radiology up to future opportunities for research and new applications.
(136) SEXUAL HEALTH CONCERNS OF OLDER WOMEN: A CROSS-SECTIONAL STUDY
Abstract Introduction Female sexual dysfunctions (FSDs) are prevalent yet underrecognized concerns among menopausal women, particularly those aged 65 and older. Age- and menopause-related sexual health issues often go unaddressed due to societal stigma and misconceptions, leading many women to attribute their symptoms to a normal part of aging. This perception limits diagnosis and treatment of conditions like hypoactive sexual desire disorder and genitourinary syndrome of menopause. Objective This study aims to compare sexual function and distress between women aged 50-64 and those aged 65 and older, with a focus on addressing critical knowledge gaps in sexual function among older women. Methods This cross-sectional study included women aged 50 and above who visited Mayo Clinic Women’s Health Clinics in Rochester, MN; Scottsdale, AZ; and Jacksonville, FL between, May 1, 2015, and August 31, 2022. Participants completed the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS-R), along with assessments of chief sexual health complaints, mood (PHQ-9), and anxiety (GAD-7) included in the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS). Results Among 4900 women included in the analysis, the median number of sexual health complaints was 2.0 in midlife (50-64 yrs) and 1.0 in older (65+ yrs) age groups (p = 0.004). Chief complaints of loss of sexual desire (47.6% vs. 33.4%; p < 0.001) and reduced genital sensation (16.9% vs. 13.0%; p = 0.024) were more common in the midlife age group. No significant differences were found in rates of complaints of vaginal dryness (51.2% vs. 52.5%; p = 0.57), painful intercourse (32.6% vs 30.7%; p = 0.38), or of difficulties with arousal or orgasm (24.0% vs 20.8%; p = 0.09). Midlife age women were also more likely to report pelvic pain (6.7% vs. 4.5%; p = 0.050), while older women reported more genital pain (8.1% vs. 5.8%; p = 0.038). FSFI scores indicated age-related differences in desire (2.4 vs. 3.0; p < 0.001), lubrication (3.9 vs. 3.6; p < 0.001), and pain (4.8 vs. 4.0; p < 0.001), aligning with the chief complaints, while arousal (3.6, p = 0.890), orgasm (4.0, p = 0.926), and satisfaction (4.4, p = 0.346) scores were similar between groups. Total FSFI scores showed no significant difference between the age groups (total = 22.2 vs 21.2, p = 0.109). Median FSDS-R scores indicated higher distress in the midlife group (15.0 vs. 13.0; p = 0.015), while overall FSD prevalence (FSFI ≤26.55 and FSDS ≥11) was similar between groups (56.2% vs 51.8%; p = 0.056). Conclusions Midlife and older women were equally likely to experience FSD in women presenting to women’s health clinics, but older women reported less distress. These results are strikingly similar to previous research indicating that while older women have FSD, there is less distress associated with it. Raising awareness and promoting open dialogue can help older women recognize that their sexual health concerns are both valid and treatable, ultimately improving quality of life. Disclosure No.